Home » Topics » BioWorld Science

BioWorld Science
RSS

BASF presents new ET antagonists

Feb. 3, 1998

New analgesic agents from Gruenenthal

Feb. 3, 1998

Heterocyclic bradykinin antagonists in development at Hoechst Marion Roussel

Feb. 3, 1998

Synthelabo claims mixed and specific dopamine receptor ligands

Feb. 3, 1998

FDA advisory panel recommends Apligraf

Feb. 3, 1998

Company Profile: Onyx

Feb. 3, 1998

Company Profile: Ribozyme

Feb. 3, 1998

Pharmacological profile of new alkylating agent from Menarini

Feb. 3, 1998

Topical interferon alfa enters phase II for intravaginal warts

Feb. 2, 1998

CBER completes review of Thymoglobulin PLA

Feb. 2, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...